DEVELOPMENT AND EVALUATION OF A TOPICAL FILM-FORMING SPRAY CONTAINING SENNA ALATA EXTRACT FOR FUNGAL INFECTIONS

Background: Topical drug delivery systems, including sprays, are gaining popularity for the treatment of skin disorders such as fungal infections. These systems allow direct application of the active drug to the affected area, offering localized treatment without the side effects associated with oral administration. In this study, a novel film-forming topical spray containing Senna alata (L.) Roxb. extract was developed for the treatment of fungal skin infections. Objective: To formulate and evaluate a film-forming spray using ethanolic extracts of Senna alata for its antifungal activity and assess its physical properties and performance in treating common dermatophyte infections. Methods: The ethanolic extract of Senna alata was incorporated into three different formulations of a film-forming spray. The spray's components included Isopropyl Alcohol (IPA), Isopropyl Myristate (IPM), Propylene Glycol (PG), and various polymers like Carbopol 940, HPMC, and CMC. The physical properties of the formulations, such as pH, viscosity, drying time, and stickiness, were evaluated. The antifungal efficacy was tested against three fungal species: Aspergillus flavus, Penicillium spp., and Candida albicans, using the zone of inhibition method. Results: The film-forming sprays demonstrated favorable physical characteristics, including non-sticky films, optimal pH, and appropriate viscosity. Formulations F1 and F2 showed significant antifungal activity against Aspergillus flavus and Penicillium spp., with zones of inhibition up to 18 mm. However, all formulations exhibited reduced efficacy against Candida albicans compared to the standard ketoconazole. Conclusion: The developed Senna alata extract-based topical spray was successful in enhancing the antifungal effects on selected dermatophytes, demonstrating its potential as an alternative treatment for fungal skin infections. Further optimization and clinical trials are needed to confirm its efficacy and safety in broader populations.